TY - JOUR
T1 - Bupropion SR for the treatment of smokeless tobacco use
AU - Dale, Lowell C.
AU - Ebbert, Jon O.
AU - Glover, Elbert D.
AU - Croghan, Ivana T.
AU - Schroeder, Darrell R.
AU - Severson, Herbert H.
AU - Hurt, Richard D.
N1 - Funding Information:
This project and manuscript was supported by the National Cancer Institute R01 9088. We would like to thank the excellent support we received from the research staff in the Nicotine Dependence Center and Stephanie Bagniewski for data analysis support. We would like to thank Penny N. Glover, M.Ed., Connie L. Cerullo, M.S., and Carl R. Sullivan, M.D., from the West Virginia University School of Medicine. The authors have no conflicts of interest to report.
PY - 2007/9/6
Y1 - 2007/9/6
N2 - Background: No pharmacotherapies have been shown to increase long-term (≥6 months) tobacco abstinence rates among smokeless tobacco (ST) users. Bupropion SR has demonstrated potential efficacy for ST users in pilot studies. We conducted a multicenter, randomized, double-blind, placebo-controlled, clinical trial to assess the efficacy and safety of bupropion SR for tobacco abstinence among ST users. Methods: Adult ST users were randomized to bupropion SR titrated to 150 mg twice daily (N = 113) or placebo (N = 112) for 12 weeks plus behavioral intervention. The primary endpoint was the 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included prolonged and continuous tobacco abstinence rates, craving and nicotine withdrawal, and weight gain. Results: The 7-day point-prevalence tobacco abstinence rates did not differ between bupropion SR and placebo at the end treatment (53.1% versus 46.4%; odds ratio (OR) 1.3; p = 0.301). The 7-day point-prevalence abstinence did not differ at weeks 24 and 52. The prolonged and continuous tobacco abstinence rates did not differ at weeks 12, 24, and 52. A time-by-treatment interaction was observed in craving over time with greater decreases in the bupropion SR group. At 12 weeks, the mean (±S.D.) weight change from baseline among abstinent subjects was an increase of 1.7 (±2.9) kg for the bupropion SR group compared to 3.2 (±2.7) kg for placebo (p = 0.005). Conclusions: Bupropion SR did not significantly increase tobacco abstinence rates among ST users, but it significantly decreased craving and weight gain over the treatment period.
AB - Background: No pharmacotherapies have been shown to increase long-term (≥6 months) tobacco abstinence rates among smokeless tobacco (ST) users. Bupropion SR has demonstrated potential efficacy for ST users in pilot studies. We conducted a multicenter, randomized, double-blind, placebo-controlled, clinical trial to assess the efficacy and safety of bupropion SR for tobacco abstinence among ST users. Methods: Adult ST users were randomized to bupropion SR titrated to 150 mg twice daily (N = 113) or placebo (N = 112) for 12 weeks plus behavioral intervention. The primary endpoint was the 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included prolonged and continuous tobacco abstinence rates, craving and nicotine withdrawal, and weight gain. Results: The 7-day point-prevalence tobacco abstinence rates did not differ between bupropion SR and placebo at the end treatment (53.1% versus 46.4%; odds ratio (OR) 1.3; p = 0.301). The 7-day point-prevalence abstinence did not differ at weeks 24 and 52. The prolonged and continuous tobacco abstinence rates did not differ at weeks 12, 24, and 52. A time-by-treatment interaction was observed in craving over time with greater decreases in the bupropion SR group. At 12 weeks, the mean (±S.D.) weight change from baseline among abstinent subjects was an increase of 1.7 (±2.9) kg for the bupropion SR group compared to 3.2 (±2.7) kg for placebo (p = 0.005). Conclusions: Bupropion SR did not significantly increase tobacco abstinence rates among ST users, but it significantly decreased craving and weight gain over the treatment period.
KW - Bupropion
KW - Smokeless
KW - Tobacco
KW - Tobacco use cessation
UR - http://www.scopus.com/inward/record.url?scp=34250641512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250641512&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2007.02.008
DO - 10.1016/j.drugalcdep.2007.02.008
M3 - Article
C2 - 17353101
AN - SCOPUS:34250641512
SN - 0376-8716
VL - 90
SP - 56
EP - 63
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
IS - 1
ER -